Some women treated for ER-positive breast cancer are at higher risk for recurrence after completing tamoxifen treatment. Now a new US study suggests that by measuring a genetic biomarker, it may be possible to predict which women will have this higher risk, thus sparing a lot of women from treatment they don't need...
More...
Linear Mode
